Citicoline

Other psychostimulants and nootropics

ATC code: N06BX06

Brand names: Somazina, Ceraxon, NeurAxon

Updated 19 Jun 2026 · Methodology

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Acute ischemic stroke

Not recommended

Citicoline is a neuroprotectant promoted for recovery after acute ischemic stroke. Trials have not shown convincing benefit for this use: it does not meaningfully change outcome or functional recovery. What actually helps in the acute phase is fast restoration of blood flow (thrombolysis and/or thrombectomy within the treatment window) plus care in a stroke unit. The substance itself is harmless here, but do not use it instead of treatment with proven benefit, or you lose time that effective treatment needs.

Standard therapy for acute ischemic stroke in international practice includes thrombolysis, thrombectomy, antiplatelets, and risk factor control. Citicoline is not part of evidence-based therapy.

Sources

ICD-10: I63 · ICD-11: 8B11

Post-stroke cognitive impairment

Not recommended

Citicoline is a compound promoted to help restore memory and attention after a stroke. Studies have not shown convincing benefit for post-stroke cognitive impairment, and there is no solid evidence base for this use. What actually improves thinking and speech after a stroke is early neurorehabilitation – speech therapy, cognitive training, physical therapy – along with managing blood pressure, blood sugar and other risk factors for a repeat stroke. Citicoline is harmless in this role, but don't use it in place of rehabilitation and the proven treatment your doctor prescribes, or you risk missing the care that truly helps.

Sources

ICD-10: I69.3 · ICD-11: 8B25

Traumatic brain injury

Not recommended

Citicoline is a compound promoted as a neuroprotectant for recovery after traumatic brain injury. Convincing benefit for this use has not been shown – there is no solid evidence that it improves outcomes. What actually makes a difference after TBI is timely care, monitoring, and rehabilitation guided by the treating team. Do not use citicoline in place of treatment with proven benefit, since that can mean missing care that truly helps.

Sources

ICD-10: S06 · ICD-11: NA07

Vascular dementia

Not recommended

Citicoline is marketed as a way to protect neurons and improve blood flow to the brain, including in vascular dementia. Clear benefit for this specific use has not been shown: there is no solid evidence that it changes cognition or the course of the disease. What actually helps in vascular dementia is managing risk factors – blood pressure, blood sugar, lipids – and working with a doctor on related conditions. Citicoline is harmless, but it should not replace treatment with proven benefit, or you may miss the care you need.

Sources

ICD-10: F01 · ICD-11: 6D81

How to read tiers A–F

AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit

Mechanism of action

Citicoline (cytidine 5'-diphosphocholine, CDP-choline) is an intermediate in the biosynthesis of phosphatidylcholine, a major phospholipid of neuronal membranes. After oral or intravenous administration it is hydrolysed to cytidine and choline, which enter brain phospholipid metabolism. Proposed mechanisms include membrane phospholipid synthesis support, acetylcholine precursor supply and reduction of free fatty acid release after ischaemic injury. Citicoline is registered as a prescription drug in Russia, Spain, Italy, Japan and several Latin American countries, and is sold as a dietary supplement in the United States. The has not approved citicoline as a pharmaceutical product for any indication. Mechanism is plausible but downstream clinical translation has not been confirmed in adequately powered modern trials.

Safety

Contraindications

Hypersensitivity to citicoline
Severe parasympathetic hypertonia
Pregnancy – due to insufficient data
Breastfeeding – due to insufficient data
Age under 18 – due to insufficient data

Serious adverse effects

In clinical RCTs, mostly mild-to-moderate adverse events are reported (hypotension, insomnia, headache)
Serious adverse events specifically attributed to the drug are not described

Common adverse effects

Headache
Insomnia
Nausea
Decreased or increased blood pressure
Hot flushes

Uncommon adverse effects

Allergic reactions (rash, pruritus)
Bradycardia
Tremor

Pregnancy: can you take Citicoline?

AEMPS summary of product characteristics (section 4.6): there are not enough data on citicoline use in pregnant women. Citicoline should not be used during pregnancy unless clearly necessary, that is, only when the expected therapeutic benefit outweighs any possible risk.

Breastfeeding: can you take Citicoline?

Use during breastfeeding is contraindicated due to insufficient data on milk penetration and infant safety.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Timing and administration

In Russia the drug is available as oral solution, 500 mg tablets, and parenteral 1000 mg IM or IV. If ineffective after 6–12 weeks, continued use is not justified. Not used in international guidelines, so no standardized regimens exist.

Monitoring

No specific monitoring required. Efficacy is assessed clinically. If no clinically meaningful improvement after 6–12 weeks, discontinue. Routine laboratory tests for therapy monitoring are not foreseen.

Special situations

The drug should not be used as a substitute for evidence-based therapy. Acute ischemic stroke relies on thrombolysis, thrombectomy, and antiplatelets; TBI on neurosurgical care and intracranial pressure management; vascular dementia on control of blood pressure, diabetes, dyslipidemia. Adding citicoline should not delay or replace evidence-based treatment.

Common myths

Myth: "Ceraxon treats stroke and restores the brain". Fact: large RCTs (ICTUS 2012, over 2000 patients) and the Cochrane 2020 review showed no improvement in acute ischemic stroke outcomes versus placebo. Recovery comes from rehabilitation, not citicoline.

Myth: "citicoline is a proven neuroprotector". Fact: international guidelines ( 2023, , ) do not include citicoline in standard care due to lack of evidence.

Myth: "Neuraxon improves memory in vascular dementia". Fact: vascular dementia management relies on control of blood pressure, diabetes, dyslipidemia; unproven neuroprotectors do not replace this approach.

Myth: "after TBI one needs course-based citicoline for recovery". Fact: the COBRIT RCT (2012) showed no improvement in functional and cognitive recovery in TBI. Recovery comes from rehabilitation.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Citicoline used for?

Citicoline is evaluated for the following indications with varying evidence strength: Post-stroke cognitive impairment (evidence tier D), Acute ischemic stroke (evidence tier D), Vascular dementia (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Citicoline?

Common side effects of Citicoline (≥ 1 in 100): Headache, Insomnia, Nausea, Decreased or increased blood pressure, Hot flushes. See the Safety section for uncommon and serious reactions.

Is Citicoline safe during pregnancy?

Is Citicoline compatible with breastfeeding?

Use during breastfeeding is contraindicated due to insufficient data on milk penetration and infant safety.

Who should not take Citicoline?

Citicoline is contraindicated in: Hypersensitivity to citicoline; Severe parasympathetic hypertonia; Pregnancy – due to insufficient data; Breastfeeding – due to insufficient data; Age under 18 – due to insufficient data. Full list in the Safety section.

Ceraxon treats stroke and restores the brain

large RCTs (ICTUS 2012, over 2000 patients) and the Cochrane 2020 review showed no improvement in acute ischemic stroke outcomes versus placebo. Recovery comes from rehabilitation, not citicoline.

citicoline is a proven neuroprotector

international guidelines (ESO 2023, AHA/ASA, AAN) do not include citicoline in standard care due to lack of evidence.

Neuraxon improves memory in vascular dementia

vascular dementia management relies on control of blood pressure, diabetes, dyslipidemia; unproven neuroprotectors do not replace this approach.

after TBI one needs course-based citicoline for recovery

the COBRIT RCT (2012) showed no improvement in functional and cognitive recovery in TBI. Recovery comes from rehabilitation.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Cortexin (bovine brain cortex polypeptides), Donepezil, Duloxetine, Escitalopram, Ginkgo biloba extract, Moclobemide, Piracetam + cinnarizine, Vortioxetine